文献速递肾移植

中和抗体介导的反应与BK病毒相关肾病风险

Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy.
PubMed 文献 · J Am Soc Nephrol · 2017-10-17

前瞻性纵向研究纳入168例肾移植受者和69例匹配供者,移植时检测BK病毒DNA载量和基因型特异性中和抗体滴度并随访24个月。52例(31%)出现BK病毒复制,其中24例仅尿毒症、28例病毒血症(含13例活检确诊BKVAN)。高滴度中和抗体与较低病毒血症风险相关,受者移植前中和谱与后续复制株基因型不匹配显著增加病毒血症风险。

要点

  • 移植前BK病毒基因型特异性中和抗体滴度或可预测移植后BK病毒复制风险。
  • 针对复制株的高中和抗体滴度与病毒血症风险降低相关(HR 0.44)。
  • 受者移植前中和谱与后续复制株基因型不匹配增加病毒血症风险(HR 2.27)。

核心结论

  • BK病毒基因型特异性中和抗体滴度可能是有意义的预测标志物,可在移植前后对患者进行BKV疾病风险分层。

研究设计与样本

  • 前瞻性纵向研究,纳入168例肾移植受者和69例匹配供者,移植时检测BK病毒DNA载量和中和抗体滴度,随访24个月。

主要发现

  • 移植后52例(31%)患者出现BK病毒复制,其中24例(46%)为尿毒症、28例(54%)为病毒血症,包括13例活检确诊BKVAN。
  • 针对复制株的高中和抗体滴度与较低病毒血症风险相关(HR 0.44;95%CI 0.26至0.73;P=0.002),中和抗体滴度每增加1 log10,病毒血症风险降低56%。
  • 早期BK病毒复制病例中,95%的复制株与供者传播一致。
  • 受者移植前中和谱与后续复制株基因型不匹配显著增加病毒血症风险(HR 2.27;95%CI 1.06至4.88;P=0.04)。
  • 移植前针对供者株的中和抗体滴度<4 log10与移植后BK病毒复制显著相关(HR 1.88;95%CI 1.06至3.45;P=0.03)。

临床怎么用

  • 可考虑在移植前检测BK病毒基因型特异性中和抗体滴度,辅助识别移植后BKV复制高风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BK virus-associated nephropathy (BKVAN) causes renal allograft dysfunction. The current management of BKVAN relies on pre-emptive adaptation of immunosuppression according to viral load monitoring. However, this empiric strategy is not always successful. Therefore, pretransplant predictive markers are needed. In a prospective longitudinal study, we enrolled 168 kidney transplant recipients and 69 matched donors. To assess the value of BKV genotype-specific neutralizing antibody (NAb) titers as a predictive marker for BKV replication, we measured BKV DNA load and NAb titers at transplant and followed patients for 24 months. After transplant, 52 (31%) patients displayed BKV replication: 24 (46%) patients were viruric and 28 (54%) patients were viremic, including 13 with biopsy-confirmed BKVAN. At any time, patients with high NAb titers against the replicating strain had a lower risk of developing BKV viremia (hazard ratio [HR], 0.44; 95% confidence interval [95% CI], 0.26 to 0.73; P=0.002). Each log10 increase in NAb titer decreased the risk of developing viremia by 56%. Replicating strains were consistent with donor transmission in 95% of cases of early BKV replication. Genotype mismatch between recipients' neutralization profiles before transplant and their subsequently replicating strain significantly increased the risk of developing viremia (HR, 2.27; 95% CI, 1.06 to 4.88; P=0.04). A NAb titer against the donor's strain <4 log10 before transplant significantly associated with BKV replication after transplant (HR, 1.88; 95% CI, 1.06 to 3.45; P=0.03). BKV genotype-specific NAb titers may be a meaningful predictive marker that allows patient stratification by BKV disease risk before and after transplant.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Solis M, Velay A, Porcher R, et al. Neutralizing Antibody-Mediated Response and Risk of BK Virus-Associated Nephropathy. J Am Soc Nephrol. 2017. PMID: 29042457. doi:10.1681/ASN.2017050532

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。